Approximately 13% of women and 10% of men in the population aged ≥60 years suffer from knee osteoarthritis (KOA) in the USA.
KOA is a degenerative inflammatory disease affecting the entire joint and is characterised by progressive loss of cartilage and associated with pain, disability and reduced quality of life (QoL).
Increased inflammatory activity is associated with higher pain intensity and more rapid KOA disease progression.
Some of the conservative intervention options for KOA are exercise therapy, non-steroidal anti-inflammatory drugs (NSAIDs) and anti-inflammatory low-level laser therapy (LLLT).
